DNX-2401 oncolytic adenovirus phase 1 trial results - Hallo friendsTOP POLENNEWS, In the article you read this time with the title DNX-2401 oncolytic adenovirus phase 1 trial results, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cultur, Article economic, Article health, Article news, Article politique, Article sport, We write this you can understand. Alright, good read.

Title : DNX-2401 oncolytic adenovirus phase 1 trial results
link : DNX-2401 oncolytic adenovirus phase 1 trial results

DNX-2401 oncolytic adenovirus phase 1 trial results

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma (click here for abstract)

I've uploaded the full PDF to the Brain Tumor Library -> 1. Therapies - human studies -> DNX-2401

In group A, 5 out of 25 patients (20%) lived for at least 3 years post-injection of DNX-2401, and three of these (12%) had dramatic responses (at least 95% reduction in cross-sectional area of enhancing tumor) and at least three years of progression-free survival.

This therapy is currently being tested in combination with pembrolizumab (anti-PD-1).

https://clinicaltrials.gov/ct2/show/NCT02798406

Thus Article DNX-2401 oncolytic adenovirus phase 1 trial results

That's an article DNX-2401 oncolytic adenovirus phase 1 trial results This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article DNX-2401 oncolytic adenovirus phase 1 trial results with the link address https://polennews.blogspot.com/2018/02/dnx-2401-oncolytic-adenovirus-phase-1.html

Tweet

Subscribe to receive free email updates: